Company Overview - AirSculpt Technologies, Inc. is a national provider of premium body contouring procedures, focusing on next-generation treatments that optimize comfort and precision [1][3] - The company's minimally invasive procedure removes fat and tightens skin, allowing for quick healing with minimal bruising and precise results [3] Leadership Appointment - Mike Doyle has been appointed as the Non-Executive Chairman of the Board of Directors, bringing over 30 years of leadership experience in the multi-center healthcare sector [1][2] - Doyle has a strong background in building successful multi-site healthcare organizations and has held several leadership positions, including CEO of Surgery Partners, where he scaled the organization from 3 to over 175 locations [2] Strategic Vision - The CEO of AirSculpt, Yogi Jashnani, expressed enthusiasm about Doyle's appointment, highlighting his experience in partnering with surgeons and developing new centers and service lines as the company enters a new phase of transformation [2] - Doyle emphasized his excitement to work with the management team to capture new market opportunities and create value for all stakeholders [2]

Core Insights - AirSculpt Technologies reported a decline in third quarter revenue and case volume, but remains optimistic about future growth opportunities driven by market trends in aesthetics and GLP-1 usage [2][8]. Financial Performance - Third quarter 2025 revenue decreased by 17.8% to $35.0 million from $42.5 million in Q3 2024 [8]. - Case volume for Q3 2025 was 2,780, down 15.2% from 3,277 in Q3 2024 [8]. - Net loss for Q3 2025 was $9.5 million compared to a net loss of $6.0 million in Q3 2024 [8]. - Adjusted EBITDA for Q3 2025 was $3.0 million, down from $4.7 million in Q3 2024 [8]. Year-to-Date Results - For the first nine months of 2025, revenue declined 16.1% to $118.4 million from $141.2 million in the same period of 2024 [8]. - Year-to-date case volume was 9,248, a decline of 15.7% from 10,972 in the first nine months of 2024 [8]. - Net loss for the first nine months of 2025 was $13.0 million compared to $3.2 million in the same period of 2024 [8]. - Adjusted EBITDA for the first nine months of 2025 was $12.6 million, down from $18.9 million in 2024 [8]. Liquidity and Financial Position - As of September 30, 2025, the company had $5.4 million in cash and cash equivalents, with an additional $5.0 million borrowing capacity under its revolving credit facility [7]. - The company generated $5.6 million in operating cash flow for the nine months ended September 30, 2025, compared to $6.8 million for the same period in 2024 [7]. Strategic Initiatives - The CEO highlighted ongoing initiatives focused on growth opportunities, margin improvement, and debt reduction, with a positive outlook for same-store sales trends entering Q4 2025 [2]. - The company has reduced debt by $18 million and delivered positive cash flow year-to-date [2]. Management Changes - Michael Arthur has been appointed as the new Chief Financial Officer, effective January 5, 2026, bringing extensive public market experience [3].

Company Overview - AirSculpt Technologies, Inc. is an industry leader in premium body contouring procedures [1] - The company offers a next-generation body contouring treatment that emphasizes comfort and precision, available exclusively at its offices [3] Financial Results Announcement - AirSculpt will report its third quarter 2025 financial results before the market opens on November 7, 2025 [1] - A conference call will follow the results announcement at 8:30 a.m. Eastern Time on the same day [1] Conference Call Access - The conference call can be accessed via a toll-free domestic number or an international number, using a specific conference ID [2] - A live webcast of the call will be available on the investor relations section of the AirSculpt website, with a replay accessible for approximately 90 days [2]

Group 1 - AirSculpt Technologies, Inc. will participate in the Sidoti Micro Cap Conference virtually on August 20-21, 2025, with a presentation scheduled for 10:00am ET on August 20 [1] - The presentation will be available for live webcast and archived for 90 days [1] Group 2 - AirSculpt offers a next-generation body contouring treatment that is minimally invasive, designed to remove fat and tighten skin while allowing for quick healing and minimal bruising [2] - The procedure aims to provide precise results in sculpting targeted areas of the body [2]

Core Insights - AirSculpt Technologies, Inc. reported a revenue decline of 13.7% year-over-year for Q2 2025, totaling $44.0 million compared to $51.0 million in Q2 2024 [8] - The company narrowed its year-over-year revenue decline by four percentage points compared to Q1 2025, indicating a potential recovery trend [2] - AirSculpt's case volume decreased by 14.1% in Q2 2025, with 3,392 cases compared to 3,949 in Q2 2024 [8] Financial Performance - For the first six months of 2025, revenue declined 15.5% to $83.4 million from $98.6 million in the same period of 2024 [8] - The net loss for Q2 2025 was $0.6 million, an improvement from a net loss of $3.2 million in Q2 2024 [8] - Adjusted EBITDA for Q2 2025 was $5.8 million, down from $6.9 million in Q2 2024, reflecting a decrease in profitability [8] Strategic Initiatives - The company is piloting two new offerings: skin tightening procedures and expanded financing options for consumers, aimed at enhancing growth strategies [2] - AirSculpt has successfully reduced its debt by $16 million in Q2 2025 following a common stock offering in June [2] - The company maintains its full-year 2025 revenue and adjusted EBITDA guidance, projecting revenues between $160 million and $170 million and adjusted EBITDA of approximately $16 million to $18 million [5][8] Liquidity and Capital Structure - As of June 30, 2025, AirSculpt had $8.2 million in cash and cash equivalents, with an additional $5.0 million available under its revolving credit facility [6] - The company generated $5.9 million in operating cash flow for the first half of 2025, compared to $6.8 million for the same period in 2024 [6] - AirSculpt's total liabilities decreased to $107.2 million from $130.7 million year-over-year, indicating improved financial health [24]

Core Viewpoint - AirSculpt Technologies, Inc. has successfully completed a common stock offering, generating net proceeds of approximately $13.8 million, which will be used to prepay $10 million of its outstanding term loan debt, enhancing its capital structure and financial flexibility [1][2]. Financial Performance - The company has prepaid $10 million of its outstanding debt, improving its capital structure [1][2]. - After the stock offering, AirSculpt has 62,436,670 shares of common stock outstanding [2]. - The company retains full availability of $5 million under its revolving credit facility after making a remaining payment of $2.9 million on June 16, 2025 [2]. Strategic Initiatives - The prepayment of debt is part of the company's strategy to advance its transformation and position itself for sustained long-term growth in revenue and profitability [2]. - The company does not anticipate the need for additional material capital raises this year, assuming no significant changes in the macroeconomic environment [1]. Product Offering - AirSculpt provides a next-generation body contouring treatment that is minimally invasive, designed to optimize comfort and precision, allowing for quick healing with minimal bruising and precise results [3].

Core Viewpoint - AirSculpt Technologies, Inc. has successfully closed a public offering of 3,160,000 shares of common stock, with an additional 474,000 shares purchased by the underwriter, resulting in estimated proceeds of approximately $13.8 million after expenses [1][2]. Group 1: Offering Details - The public offering was underwritten by Leerink Partners, who acted as the sole bookrunner [2]. - The majority of the net proceeds from the offering will be used for prepaying a portion of the Company's outstanding debt under its existing credit agreement, while the remainder will be allocated for general corporate purposes, including working capital and other business opportunities [2]. Group 2: Regulatory Information - A shelf registration statement for the shares was filed with the Securities and Exchange Commission (SEC) and became effective on March 24, 2025 [3]. - A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are accessible on the SEC's website [3]. Group 3: Company Overview - AirSculpt is a provider of next-generation body contouring treatments, focusing on comfort and precision, with procedures designed to remove fat and tighten skin while allowing for quick healing and minimal bruising [5].

Core Viewpoint - AirSculpt Technologies, Inc. has announced a public offering of 3,160,000 shares of common stock priced at $3.80 per share, aiming to raise $12.0 million before expenses [1][2]. Group 1: Offering Details - The company has granted the underwriter a 30-day option to purchase up to 474,000 additional shares at the same price [1]. - The offering is expected to close on or about June 11, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - A majority of the net proceeds from the offering will be used for the prepayment of a portion of the company's outstanding indebtedness under its existing credit agreement [2]. - The remainder of the net proceeds will be allocated for general corporate purposes, including working capital and other business opportunities [2]. Group 3: Company Overview - AirSculpt is a provider of next-generation body contouring treatments designed for comfort and precision, focusing on minimally invasive procedures that remove fat and tighten skin [5].

Core Viewpoint - AirSculpt Technologies, Inc. has announced a public offering of 3,160,000 shares of its common stock, with an additional option for underwriters to purchase up to 474,000 shares [1][2]. Group 1: Offering Details - The public offering consists of 3,160,000 shares of common stock, with a 30-day option for underwriters to buy an additional 474,000 shares [1]. - Vesey Street Capital Partners, the largest stockholder, is interested in purchasing up to $4.0 million in shares from the offering [2]. - Leerink Partners is acting as the sole bookrunner for the offering [3]. Group 2: Use of Proceeds - A portion of the net proceeds from the offering will be used to prepay part of the Company's outstanding debt under its existing credit agreement [3]. - The remaining proceeds will be allocated for general corporate purposes, including working capital and other business opportunities [3]. Group 3: Regulatory Information - A shelf registration statement for the shares was filed with the Securities and Exchange Commission and became effective on March 24, 2025 [4].

Core Insights - AirSculpt Technologies, Inc. reported first-quarter results for 2025, indicating a focus on returning to growth through strategic initiatives and cost management [1][2]. Financial Performance - Case volume for Q1 2025 was 3,076, a decline of 17.9% from 3,746 in Q1 2024 [6][22]. - Revenue decreased by 17.3% to $39.4 million from $47.6 million in the same quarter of the previous year [6][17]. - The company reported a net loss of $2.8 million compared to a net income of $6.0 million in Q1 2024 [6][17]. - Adjusted EBITDA was $3.8 million, down from $7.3 million in Q1 2024, with an adjusted EBITDA margin of 9.5% compared to 15.4% [6][22]. Strategic Initiatives - The CEO expressed confidence in the company's transformation efforts and highlighted the early benefits from a new go-to-market strategy, which has improved lead volumes and revenue decline [2]. - The company is focusing on increasing lead generation, consultations, and case conversions through enhanced marketing and sales efforts [2]. - AirSculpt is piloting a standalone skin tightening service, which has garnered increasing interest, positioning the company to capitalize on this opportunity [2]. Liquidity and Cash Flow - As of March 31, 2025, the company had $5.6 million in cash and cash equivalents, down from $8.2 million at the end of 2023 [5][19]. - Operating cash flow for Q1 2025 was $0.9 million, a decrease from $3.4 million in Q1 2024 [5][21]. 2025 Outlook - The company projects full-year 2025 revenue between $160 million and $170 million, with adjusted EBITDA guidance of approximately $16 million to $18 million [4][6].